Sulindac
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Sulindac: Acromesomelic dysplasia, Hunter-Thompson type
One-Sentence Summary
Sulindac is a non-steroidal anti-inflammatory drug (NSAID) originally used for inflammatory joint and soft-tissue conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout, bursitis and tendinitis. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, a rare genetic skeletal disorder, but there are 0 clinical trials and 0 publications supporting this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 0.9992 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, sulindac is a cyclooxygenase (COX) inhibitor NSAID, its efficacy in inflammatory musculoskeletal conditions is established, and it is used to relieve pain and inflammation in joints and soft tissues.
For the predicted condition, however, the rationale is weak. Acromesomelic dysplasia, Hunter-Thompson type, is a genetic skeletal dysplasia caused by loss-of-function variants in the CDMP1/GDF5 gene. This gene is part of the BMP/GDF5 signalling pathway, which sulindac does not target. No established mechanistic link exists between COX inhibition and correction of this defect.
The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. At best, an NSAID could relieve joint pain symptomatically, which falls within existing class use and would not be true repurposing.
Other top-ranked predictions show the same pattern. These include brachyolmia, pseudoachondroplasia, brachydactyly-syndactyly syndrome and WHIM syndrome. All have no clinical or literature evidence and little or no mechanistic plausibility.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00745596 | TEVA-SULINDAC | Not specified | Not specified |
| 00745588 | TEVA-SULINDAC | Not specified | Not specified |
Safety Considerations
- Contraindications and risk conditions (from the knowledge graph, not label text): The knowledge graph links sulindac to the following conditions, which signal caution.
- Cardiovascular: hypertension, congestive heart failure, myocardial infarction, coronary thrombosis, cardiovascular disease
- Gastrointestinal: active peptic ulcer disease
- Renal and hepatic: kidney disease, liver disease, nephrolithiasis, acute urate nephropathy
- Haematological: blood coagulation disease, anaemia, hemoglobinopathy
- Autoimmune and connective tissue: systemic lupus erythematosus, connective tissue disease
- Other: gallbladder disease, bone and cartilage disease, substance abuse/dependence
- Drug Interactions: The interaction screen returned 100 records. The 20 retrieved included mainly Moderate and some Minor interactions.
- Moderate: corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone), acetylsalicylic acid, metformin, sulfonylureas (glimepiride, chlorpropamide), mesalazine, balsalazide, potassium salts (potassium citrate, potassium bicarbonate), and bowel-preparation agents (picosulfuric acid, polyethylene glycol with electrolytes, sodium sulfate)
- Minor: H2 blockers (famotidine, ranitidine, cimetidine) and linaclotide
Package insert warnings and contraindications could not be retrieved. Please refer to the package insert for the full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is computational only (L5), with no clinical trials or publications. Sulindac has no plausible mechanistic link to the GDF5-driven genetic defect in this condition. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
To proceed, the following is needed:
- Any preclinical or mechanistic evidence connecting COX inhibition to GDF5/BMP signalling or skeletal growth in this condition
- Mechanism of action data for sulindac
- Health Canada package insert warnings and contraindications, which is a blocking gap for safety screening
- A clear definition of the intended use. If it is only symptomatic joint pain relief, this is already within the NSAID class and is not a new indication.
- Consideration of other predicted indications only if supporting clinical evidence emerges. The current evidence there is also lacking.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.